# Tesamorelin + Ipamorelin

> Combination — not ranked · Combos · reviewed 2026-11-08
> Source page: https://peptidemeta.com/p/tesamorelin-ipamorelin/

## Quick answers

**What is Tesamorelin + Ipamorelin?**

A potent GH blend combining the FDA-approved GHRH analog Tesamorelin with Ipamorelin for targeted visceral fat reduction and comprehensive growth hormone optimization. Tesamorelin (stabilized GHRH analogue) plus ipamorelin.

**What is in Tesamorelin + Ipamorelin?**

Tesamorelin + Ipamorelin typically combines Tesamorelin and Ipamorelin. Commercial products vary.

**How strong is the evidence for Tesamorelin + Ipamorelin?**

It is not ranked. A PubMed search found no published studies of this combination; only reviews mention it. Tesamorelin alone is FDA-approved (Egrifta) on the strength of phase 3 RCTs; ipamorelin has small human pharmacology studies.

**Is Tesamorelin + Ipamorelin FDA-approved?**

No. Tesamorelin + Ipamorelin is not an approved product; no regulator has reviewed the combination. Only tesamorelin on its own is approved (Egrifta); the combination is not.

**Is Tesamorelin + Ipamorelin banned in sport?**

Yes. Tesamorelin + Ipamorelin is prohibited in sport by the World Anti-Doping Agency under S2 (peptide hormones, growth factors, related substances and mimetics).

**How does Tesamorelin + Ipamorelin work?**

This blend pairs the FDA-approved GHRH analog tesamorelin (which activates GHRH receptor/cAMP signaling with enhanced enzymatic stability) with ipamorelin (selective ghrelin receptor agonist). Tesamorelin specifically targets visceral fat reduction through GH-mediated lipolysis, while ipamorelin amplifies the GH pulse without cortisol or prolactin elevation.

**What is known about the safety of Tesamorelin + Ipamorelin?**

Tesamorelin is FDA-approved (Egrifta) with Phase III safety data. Ipamorelin has Phase II human data.

## Key facts

- **Evidence tier:** not ranked
- **FDA:** not approved
- **WADA:** prohibited (S2)
- **Peptide:** yes
- **Routes studied:** Subcutaneous, Intramuscular
- **Components:** Tesamorelin, Ipamorelin

## Overview

A potent GH blend combining the FDA-approved GHRH analog Tesamorelin with Ipamorelin for targeted visceral fat reduction and comprehensive growth hormone optimization.

## Mechanism

This blend pairs the FDA-approved GHRH analog tesamorelin (which activates GHRH receptor/cAMP signaling with enhanced enzymatic stability) with ipamorelin (selective ghrelin receptor agonist). Tesamorelin specifically targets visceral fat reduction through GH-mediated lipolysis, while ipamorelin amplifies the GH pulse without cortisol or prolactin elevation.

## Effects reported in research

_Reported outcomes, not promises; see the evidence tier._

- Significant visceral fat reduction
- Robust GH and IGF-1 elevation
- Improved lipid profiles
- Enhanced body composition and recovery

## Safety & unknowns

Tesamorelin is FDA-approved (Egrifta) with Phase III safety data. Ipamorelin has Phase II human data. Combined side effects may include injection site reactions, arthralgia, water retention, headache. Tesamorelin is contraindicated in active malignancy and pregnancy. Monitor IGF-1 levels. Not FDA-approved as a combination.

## Studies

- Falutz J, Allas S, Blot K, et al. (2007). *Metabolic effects of a growth hormone-releasing factor in patients with HIV*. New England Journal of Medicine. Clinical trial. https://pubmed.ncbi.nlm.nih.gov/18057338/
  Phase 3 RCT of the tesamorelin component in HIV patients with abdominal fat accumulation: visceral fat fell 15.2% with tesamorelin versus a 5.0% rise with placebo over 26 weeks.
- Raun K, Hansen BS, Johansen NL, et al. (1998). *Ipamorelin, the first selective growth hormone secretagogue*. European Journal of Endocrinology. Preclinical. https://pubmed.ncbi.nlm.nih.gov/9849822/
  Rat and swine study on the ipamorelin component showing selective GH release without increases in ACTH or cortisol.

## Status sources

- [Drugs@FDA — NDA 022505 Egrifta (tesamorelin)](https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=022505)
- [Falutz et al. 2007 — tesamorelin phase 3 RCT (NEJM)](https://pubmed.ncbi.nlm.nih.gov/18057338/)
- [Gobburu et al. 1999 — ipamorelin PK/PD in human volunteers](https://pubmed.ncbi.nlm.nih.gov/10496658/)
- [WADA 2026 Prohibited List — S2.2.4 names tesamorelin and ipamorelin](https://www.wada-ama.org/sites/default/files/2025-09/2026list_en_final_clean_september_2025.pdf)

---

Educational reference only — not medical advice. No dosing information is published. Tiers rate the strength of published evidence, not effectiveness or safety.